Physician profile
Summer Henry
NPI 1417735630
$2,801.86
in general payments reported to CMS, 2019-2025
18 companies · $1,476 in 2025
The $1,476 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,326 · 2025: $1,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,801.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $847.10 | 2024-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $440.71 | 2024-2025 | Wegovy, Ozempic |
| Amgen INC. | $406.18 | 2024-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $199.48 | 2024-2025 | Spravato |
| Corcept Therapeutics | $141.51 | 2024-2025 | Korlym |
| Abbvie INC. | $128.51 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $110.30 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $94.68 | 2024-2025 | |
| Dexcom, INC. | $82.46 | 2024-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $70.93 | 2025 | Eliquis |
| Lilly USA, LLC | $66.05 | 2025 | Mounjaro, Zepbound |
| Paratek Pharmaceuticals, INC. | $48.23 | 2025 | Nuzyra, Xhance |
| Xeris Pharmaceuticals, INC. | $47.32 | 2025 | Recorlev, Gvoke Hypopen |
| Esperion Therapeutics, INC. | $33.55 | 2024-2025 | Nexletol |
| Pfizer INC. | $23.20 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $21.68 | 2024 | Aptima, Thinprep 2000 Processor |
| Exact Sciences Corporation | $21.56 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $18.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summer Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.